Pfizer files for U.S. authorization of promising COVID-19 antiviral pill

By Michael Erman (Reuters) – Pfizer Inc said on Tuesday it is seeking U.S. authorization of its experimental antiviral COVID-19 pill that cut the chance of hospitalization or death for adults at risk of severe disease by 89% in a clinical trial. Pfizer said it completed submission of its application for emergency use authorization (EUA) of the drug, Paxlovid, with the U.S. Food and Drug Administration, including data from the drugmaker’s clinical trial. The oral drug could be a promising new weapon in the fight against the pandemic, as it can be taken as an early at-home treatment to help prev…

Read More